Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice-Reference-Cited by-同舟云学术

Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice

Published:2018-01 Issue:1 Volume:28 Page:72-78
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Berdelou Amandine¹²,Borget Isabelle³,Godbert Yann⁴,Nguyen Thierry⁵,Garcia Marie-Eve⁶,Chougnet Cécile N.⁷,Ferru Aurélie⁸,Buffet Camille⁹,Chabre Olivier¹⁰,Huillard Olivier¹¹,Leboulleux Sophie¹,Schlumberger Martin¹,on the behalf of the TUTHYREF Netwo

Affiliation:

1. Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Université Paris–Saclay, Villejuif, France.

2. Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, Saint-Cloud, France.

3. Department of Biostatistics and Epidemiology, Gustave Roussy, CESP, and Université Paris–Saclay, Villejuif, France.

4. Department of Nuclear Medicine, Institut Bergonié, Bordeaux, France.

5. Department of Medical Oncology, Centre Hospitalier Universitaire Minjoz, Besançon, France.

6. Department of Multidisciplinary Oncology and Therapeutic Innovations, Assistance Publique-Hôpitaux de Marseille, Marseille, France.

7. Department of Nuclear Medicine and Endocrine Oncology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, France.

8. Department of Medical Oncology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.

9. Department of Endocrinology, Hôpital de la Pitié Salpêtrière, Assistance Publique-Hôpitaux de Paris and Université Pierre et Marie Curie, France.

10. Department of Endocrinology, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.

11. Department of Medical Oncology, Hopital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2017.0205

Reference12 articles.

1. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition

2. Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase

3. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

4. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

5. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Schilddrüsenkarzinome – Rolle internistischer Systemtherapien;Die Innere Medizin;2024-06-20

2. Poorly differentiated thyroid carcinoma: molecular, clinico-pathological hallmarks and therapeutic perspectives;Panminerva Medica;2024-06

3. Planned Drug Holidays Seems Safe and Effective in the Treatment of Differentiated Thyroid Cancer;Clinical Thyroidology®;2024-06-01

4. Ten years’ real-life experience on the use of multikinase inhibitors in patients with advanced differentiated thyroid cancer;Endocrine;2024-05-21

5. Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents;Cell Communication and Signaling;2024-04-15